Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04091750
Title Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Georgetown University
Indications

melanoma

Therapies

Cabozantinib + Ipilimumab + Nivolumab

Cabozantinib + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.